Insider · CIK 0001575202
Sheila Gujrathi
director
Files at JANX (Janux Therapeutics, Inc.), VTYX (Ventyx Biosciences, Inc.). First filing Dec 26, 2024, latest Dec 26, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$301k bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | VTYXbuy Ventyx Biosciences, Inc. | $301k 130,000 shares | - | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Common Stock | +3,750 | $0.00 | $0 | 118,889 | Jun 13, 2025 |
| Jun 11, 2025 | JANX Janux Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +11,667 | $0.00 | $0 | 11,667 | Jun 13, 2025 |
| Jun 5, 2025 | VTYX Ventyx Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jun 6, 2025 |
| Dec 23, 2024 | VTYX Ventyx Biosciences, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +130,000 | $2.31 | $301k | 130,000 | Dec 26, 2024 |
| Nov 5, 2024 | JANX Janux Therapeutics, Inc. | JOther Common Stock | +4,611 | $0.00 | $0 | 115,139 | Nov 7, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.